Study Overview: This study is for people with sickle cell disease (SCD), a condition where red blood cells become sickle-shaped, making it hard for blood to flow smoothly. The study tests a medicine called osivelotor to see if it is safe and helps patients. The study has three parts:
- Part A: Tests the safety and best dose of osivelotor in adults.
- Part B: Compares osivelotor with a placebo (a pill with no medicine) in adults and teens for 48 weeks.
- Part C: Looks at how osivelotor is absorbed in children's bodies and its safety.
Eligibility: To join, you must have stable hemoglobin (Hb) levels and be on a steady dose of some SCD treatments. You should not have had more than 10 vaso-occlusive crises (VOCs) in the last year. Pregnant or breastfeeding women cannot join.
Key Points:
- Participation can last up to 48 weeks.
- You may be required to visit the clinic multiple times.
- There are risks, like any study, and osivelotor's effects are still being studied.
Note: This study is not suitable if you recently had certain treatments or hospitalizations.
How understandable was the trial content above?
Hard to understand
Easy to understand